Prevalence and Predictors of Triple-Class Drug Resistance

The development of triple-class resistance is rare in patients who initiate antiretroviral therapy with a regimen that includes either a potent NNRTI or a boosted PI.

Triple-class drug resistance severely limits HIV treatment options and is therefore considered to be a marker for adverse prognosis. To determine the factors that lead to such resistance, investigators evaluated data from 1587 HIV-infected patients in North Carolina who had received antiretroviral therapy for a median of 5.7 years. Patients had been exposed to a median of six antiretroviral agents, and 47% had been exposed to all three major drug classes.

Based on viral genotypes obtained from 607 patients, 121 had triple-class drug resistance (8% of the entire cohort). In univariate analyses, triple-class resistance was associated with a lower nadir CD4-cell count, higher peak viral load, previous AIDS-defining condition, earlier calendar y…

Reviewing Author

Helmut Albrecht, MD

Prevalence and Predictors of Triple-Class Drug Resistance

Topics

Reviewing Author